Supplementary Online Content


eFigure. Patient flow diagram.

This supplementary material has been provided by the authors to give readers additional information about their work.
eFigure 1. Patient Flow Diagram

Enrollment
- Assessed for eligibility (n=45)
  - Excluded (n=10)
    - No neurologic worsening in the preceding 8 months (n=9)
    - Did not meet autoantibody criteria (n=6)
    - Declined to participate (n=2)
    - < 2 mg/dL (n=1)
    - Symptoms improved spontaneously (n=1)

Allocation
- Allocated to intervention (n=36)
  - Number of treatment events (n=54)

Follow-Up
- Lost to follow-up (n=6)
  - Discontinued intervention (n=2)
  - Worse neurologic symptoms (n=1)
  - Pneumonia (n=1)

Analysis
- Analyzed for:
  1. CSF pleocytosis pre- vs post-treatment (n=19)
    - Excluded from analysis (n=15): Not available
  2. CSF pleocytosis pre-treatment (n=29)
    - Excluded from analysis (n=6): Not available
  3. Survival (n=28)
    - Excluded from analysis (n=0)
  4. Adverse Events (n=29)
    - Excluded from analysis (n=0)